Clinical Trials Logo

Edema clinical trials

View clinical trials related to Edema.

Filter by:

NCT ID: NCT01492400 Completed - Macular Edema Clinical Trials

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Start date: March 9, 2012
Phase: Phase 2
Study type: Interventional

This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).

NCT ID: NCT01487629 Active, not recruiting - Clinical trials for Diabetic Retinopathy

Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

IBERA-DME
Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

NCT ID: NCT01487044 Available - Clinical trials for Diabetic Macular Edema

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

GUARDIAN
Start date: n/a
Phase: N/A
Study type: Expanded Access

Establish the efficacy of initial high frequency loading of intravitreal pegaptanib bi-weekly during the initial treatment period when the VEGF levels are the greatest and then gradually extending the administration frequency to monthly as homeostasis ensues for the treatment of DME, as measured by best-corrected visual acuity.

NCT ID: NCT01486238 Completed - Clinical trials for Diabetic Macular Edema

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

PRESERVE
Start date: April 2009
Phase: Phase 4
Study type: Interventional

Intravitreal injections of pegaptanib every 4 weeks will be efficacious in treating Diabetic Macular Edema (DME), as compared to injections every 6 weeks.

NCT ID: NCT01482871 Withdrawn - Clinical trials for Diabetic Macular Edema

Safety Study of ALG- 1001 to Treat Diabetic Macular Edema

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG - 1001 in human subjects with diabetic macular edema. The primary endpoint of this study is observation of dose limiting toxicity and maximum tolerated dose. The secondary endpoint of this study is observation of a clinical effect in BCVA (ETDRS letters) and OCT central macular thickness.

NCT ID: NCT01476449 Completed - Clinical trials for Diabetic Retinopathy

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

Start date: November 2011
Phase: Phase 2
Study type: Interventional

This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.

NCT ID: NCT01473251 Completed - Clinical trials for Diabetic Macular Edema

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

NCT ID: NCT01472510 Completed - Clinical trials for Diabetic Macular Edema

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This study is designed to confirm that the investigational drug Ranibizumab given by injection into the eye is safe and effective to use in people with diabetic macular edema (DME).

NCT ID: NCT01471691 Completed - Macular Edema Clinical Trials

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

RAVEN
Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

NCT ID: NCT01471054 Terminated - Macular Edema Clinical Trials

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Start date: April 2014
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema after plaque radiotherapy of uveal melanoma.